GLP-1 Prior Authorization Criteria: What Employers Are Requiring
More and more, employer-sponsored health plans are asking for prior authorization (PA) for GLP-1 receptor agonists. These drugs are mainly prescribed for managing type 2 diabetes and weight issues. Some popular GLP-1 medications are semaglutide (known as Ozempic, Wegovy, made by Novo Nordisk) and liraglutide (known as Victoza, Saxenda, also by Novo Nordisk). Generally, these drugs fall into the second or third tier in insurance formularies, affecting how much patients must pay out of pocket.
Reasons for Prior Authorization
Employers often look for PA to ensure medications are used correctly and to keep costs in check. A report from the Kaiser Family Foundation (KFF) shows that about 60% of large employers who offer health benefits require PAs for some prescriptions, including GLP-1s. The main reason is their hefty price tag; for example, semaglutide can cost over $1,000 monthly if you don't have insurance.
Common PA Criteria
Here are some typical criteria for GLP-1 PAs:
| Criteria | Description |
|---|---|
| Diagnosis Confirmation | You need to verify a type 2 diabetes diagnosis or obesity with a BMI over 30, or 27 if there are other health issues. |
| Previous Therapy | There must be proof that metformin or lifestyle changes weren't enough to control the condition. |
| Specialist Consultation | Sometimes, a specialist needs to confirm that GLP-1 therapy is necessary. |
Impact of Policy Changes
The Centers for Medicare & Medicaid Services (CMS) have noticed a gradual uptick in the management of GLP-1s because of rising costs. New PA criteria came into play on January 1, 2023. These changes affect both new and renewing plans that include these medicines, possibly leading to stricter checks before approval.
Pharmacists' Role
Pharmacists are in the PA process. They help patients gather the necessary paperwork and work with healthcare providers to meet the criteria. This support can help avoid delays in getting medication.
This information highlights a broader trend in the private insurance market, where employers aim to balance the need for new treatments with managing costs.
Disclaimer: This article is for informational purposes only and is not medical or insurance advice. Consult healthcare professionals and insurance representatives for specific coverage details.